

HÃ©lÃ¨ne CavÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8540909/publications.pdf>

Version: 2024-02-01

49
papers

2,781
citations

201674

27
h-index

214800

47
g-index

52
all docs

52
docs citations

52
times ranked

4891
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal dynamics in pediatric Bâ€cell precursor acute lymphoblastic leukemia with very early relapse. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29361.	1.5	9
2	Clinical characteristics, growth patterns, and longâ€term diabetes complications of 24 patients with neonatal diabetes mellitus: A single center experience. <i>Pediatric Diabetes</i> , 2022, 23, 45-54.	2.9	2
3	Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects. <i>ELife</i> , 2022, 11, .	6.0	9
4	Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications. <i>European Journal of Human Genetics</i> , 2021, 29, 51-60.	2.8	17
5	The clinical significance of A2ML1 variants in Noonan syndrome has to be reconsidered. <i>European Journal of Human Genetics</i> , 2021, 29, 524-527.	2.8	7
6	Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 2801.	3.3	8
7	Predisposition to cancer in children and adolescents. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 142-154.	5.6	53
8	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. <i>Leukemia</i> , 2021, 35, 3272-3277.	7.2	40
9	Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 3383-3393.	7.2	77
10	Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. <i>Leukemia</i> , 2021, 35, 2978-2982.	7.2	40
11	Oligo-astrocytoma in LZTR1-related Noonan syndrome. <i>European Journal of Medical Genetics</i> , 2020, 63, 103617.	1.3	17
12	Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. <i>Leukemia</i> , 2020, 34, 1658-1668.	7.2	14
13	Neonatal Diabetes Mellitus. <i>Frontiers in Pediatrics</i> , 2020, 8, 540718.	1.9	37
14	Pediatric randomized trial EORTC CLG 58951: Outcome for adolescent population with acute lymphoblastic leukemia. <i>Hematological Oncology</i> , 2020, 38, 763-772.	1.7	7
15	IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?. <i>Blood</i> , 2020, 135, 252-260.	1.4	77
16	Long-term Metabolic and Socioeducational Outcomes of Transient Neonatal Diabetes: A Longitudinal and Cross-sectional Study. <i>Diabetes Care</i> , 2020, 43, 1191-1199.	8.6	5
17	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. <i>Blood</i> , 2019, 134, 1351-1355.	1.4	89
18	Large deletions of the 5â€² region of IKZF 1 lead to haploinsufficiency in Bâ€cell precursor acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, e155-e159.	2.5	4

#	ARTICLE	IF	CITATIONS
19	Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions. <i>Leukemia</i> , 2019, 33, 2306-2340.	7.2	41
20	Relevant subtypes in childhood ALL. <i>HemaSphere</i> , 2019, 3, 174-177.	2.7	1
21	Long Non-Coding RNAs As Novel Therapeutic Targets in Juvenile Myelomonocytic Leukemia: Proof of Concept Study. <i>Blood</i> , 2019, 134, 1701-1701.	1.4	1
22	Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience. <i>Blood</i> , 2019, 134, 3876-3876.	1.4	9
23	ClinGen™s RASopathy Expert Panel consensus methods for variant interpretation. <i>Genetics in Medicine</i> , 2018, 20, 1334-1345.	2.4	126
24	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. <i>Haematologica</i> , 2018, 103, 107-115.	3.5	68
25	<i>IKZF1</i> ^{plus} Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1240-1249.	1.6	194
26	Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. <i>Lancet Haematology</i> , 2018, 5, e641-e652.	4.6	78
27	Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework. <i>Human Mutation</i> , 2018, 39, 1485-1493.	2.5	66
28	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <i>Haematologica</i> , 2018, 103, 1278-1287.	3.5	129
29	Noonan syndrome males display Sertoli cell-specific primary testicular insufficiency. <i>European Journal of Endocrinology</i> , 2018, 179, 409-418.	3.7	16
30	Genotype and phenotype spectrum of NRAS germline variants. <i>European Journal of Human Genetics</i> , 2017, 25, 823-831.	2.8	36
31	Prolonged <i>versus</i> standard native <i>E. coli</i> asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. <i>Haematologica</i> , 2017, 102, 1727-1738.	3.5	22
32	Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. <i>Blood Advances</i> , 2017, 1, 1473-1477.	5.2	25
33	Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia. <i>European Journal of Human Genetics</i> , 2016, 24, 1124-1131.	2.8	23
34	Growth patterns of patients with Noonan syndrome: correlation with age and genotype. <i>European Journal of Endocrinology</i> , 2016, 174, 641-650.	3.7	40
35	Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome. <i>Human Mutation</i> , 2015, 36, 1080-1087.	2.5	67
36	Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 171, 574-584.	2.5	40

#	ARTICLE	IF	CITATIONS
37	Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11 -Associated Juvenile Myelomonocytic Leukemia. <i>Cell Reports</i> , 2015, 13, 504-515.	6.4	79
38	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. <i>Nature Genetics</i> , 2015, 47, 1334-1340.	21.4	152
39	CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. <i>Haematologica</i> , 2015, 100, 1311-1319.	3.5	8
40	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 3739-3749.	1.4	281
41	Juvenile myelomonocytic leukaemia and Noonan syndrome. <i>Journal of Medical Genetics</i> , 2014, 51, 689-697.	3.2	112
42	IKZF1 status as a prognostic feature in BCR-ABL1â€“positive childhood ALL. <i>Blood</i> , 2014, 123, 1691-1698.	1.4	129
43	Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3785-3785.	1.4	0
44	Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 199-207.	11.4	87
45	Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2013, 98, 597-601.	3.5	73
46	Distinctive Genotypes In Infants With T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Blood</i> , 2013, 122, 1377-1377.	1.4	0
47	Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome. <i>Journal of Human Genetics</i> , 2008, 53, 834-841.	2.3	31
48	Somatically acquired <i>JAK1</i> mutations in adult acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2008, 205, 751-758.	8.5	318
49	Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	6